Enhabit Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Enhabit, Inc. (NYSE: EHAB) reported its Q2 2023 results, including net service revenue of $262.3 million, a net loss of $74.1 million, and adjusted EBITDA of $23.9 million. The company negotiated ten new contracts with Medicare Advantage payors and increased clinical staff with 203 net new full-time nursing hires. However, the pace of progress has not met initial guidance. The company also announced its intent to launch a strategic alternatives process, subject to conditions in the Tax Matters Agreement.

Positive

• Enhabit reported net service revenue of $262.3 million for Q2 2023.
• The company negotiated ten new contracts with Medicare Advantage payors.
• Enhabit increased clinical staff with 203 net new full-time nursing hires.
• The company's 30-day hospital readmission rate is 370 basis points better than the national average.
• Enhabit announced its intent to launch a strategic alternatives process, subject to conditions in the Tax Matters Agreement.

Negative

• Enhabit reported a net loss of $74.1 million for Q2 2023.
• Adjusted EBITDA decreased by 40.7% compared to the previous year.
• The company revised its full-year 2023 guidance, lowering net service revenue and adjusted EBITDA ranges.

Revises Full-Year Guidance

Announces Intent to Launch Strategic Alternatives Process Subject to Satisfaction of Conditions in Tax Matters Agreement

Company to host a conference call tomorrow, August 10, 2023 at 10 AM EDT

DALLAS--(BUSINESS WIRE)-- Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2023.

“During the second quarter, we negotiated ten new contracts with Medicare Advantage payors, increased our clinical staff with 203 net new full-time nursing hires, and continued to outperform the industry average with a 30-day hospital readmission rate that is 370 basis points better than the national average,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “While we continue to make progress with our strategic initiatives, the pace of the progress has not been fast enough in 2023 to meet our initial guidance. We remain confident our teams’ relentless efforts to retain staff, manage costs, and deliver high-quality care will enhance our value long term.”

QUARTERLY PERFORMANCE - CONSOLIDATED

• Net service revenue of $262.3 million
• Net loss of $74.1 million
• Adjusted EBITDA of $23.9 million
• Loss per diluted share of $1.49
• Adjusted earnings per share of $0.04

RECENT COMPANY HIGHLIGHTS

• Negotiated ten new Medicare Advantage payor contracts in the second quarter
• Shifted approximately 5% of previous non-episodic visits into non-episodic payor innovation contracts at improved per visit rates
• Continued strong growth in home health Medicare Advantage admissions with non-episodic admissions up 38.0% driving total admission growth of 3.2% year over year
• Continued recruiting success adding 203 net new full-time nursing hires in the second quarter
• Opened two de novo home health locations in Montana in April and one hospice de novo location in Texas in May
• Hospice cost per day stabilized sequentially
• 30-day hospitalization readmission rate is 370 basis points better than the national average

FINANCIAL RESULTS

Consolidated

($ in millions, except per share data)	Q2								'23 vs. '22
	2023				2022
Home health net service revenue	$		213.8		$		220.2		(2.9)%
Hospice net service revenue			48.5				47.8		1.5%
Total net service revenue	$		262.3		$		268.0		(2.1)%
	% of Revenue				% of Revenue
Cost of services	51.7%	$	(135.5)		48.6%	$	(130.3)		4.0%
Gross margin	48.3%		126.8		51.4%		137.7		(7.9)%
General & administrative expenses	39.2%		(102.7)		36.1%		(96.7)		6.2%
Operating expenses	90.8%		(238.2)		84.7%		(227.0)		4.9%
Other income			(0.1)				—
Equity earnings / noncontrolling interest			0.3				0.7
Adjusted EBITDA	$		23.9		$		40.3		(40.7)%
Adjusted EBITDA margin			9.1%				15.0%
Reported Diluted EPS	$		(1.49)		$		0.41		(467.7)%
Adjusted EPS	$		0.04		$		0.47		(91.5)%

The continued shift to more non-episodic admissions in home health and the resumption of sequestration reduced consolidated net service revenue and Adjusted EBITDA $10.5 million year over year.

Adjusted EBITDA decreased year over year primarily due to the continued shift to more non-episodic admissions in home health, incremental costs associated with being a stand-alone company, and the resumption of sequestration.

SEGMENT RESULTS

Home health

($ in millions)	Q2						'23 vs. '22
		2023			2022
Net service revenue	$	213.8		$	220.2		(2.9)%
Cost of services		111.4			108.8		2.4%
Gross margin		47.9 %			50.6 %
General & administrative expenses	$	59.4		$	57.8		2.8%
Other income	$	(0.1)		$	—
Equity earnings / noncontrolling interest	$	0.3		$	0.6		(50.0)%
Adjusted EBITDA	$	42.8		$	53.0		(19.2)%
% Adj. EBITDA margin		20.0 %			24.1 %
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions		32,628			36,106		(9.6)%
Non-episodic admissions		18,347			13,293		38.0%
Total admissions		50,975			49,399		3.2%
Same-store total admissions growth							1.7%
Episodic recertifications		23,788			25,993		(8.5)%
Non-episodic recertifications		9,554			6,447		48.2%
Total recertifications		33,342			32,440		2.8%
Same-store total recertifications growth							2.2%
Total starts of care		84,317			81,839		3.0%
Completed episodes		56,808			62,691		(9.4)%
Revenue per episode	$	2,913		$	2,972		(2.0)%
Visits per episode		14.6			15.0		(2.7)%
Total visits		1,205,865			1,217,447		(1.0)%
Non-episodic visits		377,214			275,679		36.8%
Cost per visit	$	91		$	88		3.4%

The year-over-year decrease in revenue was due primarily to the continued payor mix shift to more non-episodic admissions and the resumption of sequestration. Revenue per episode decreased year over year primarily due to the resumption of sequestration and patient mix.

Adjusted EBITDA decreased year over year primarily due to the continued payor mix shift to more non-episodic admissions, the resumption of sequestration, and increased general and administrative expenses associated with new stores. Cost per visit increased year-over-year primarily due to increased contract labor, merit and market rate increases for clinical staff, and increased costs associated with employee group medical claims partially offset by improved clinical productivity.

Hospice

($ in millions)	Q2						'23 vs. '22
	2023			2022
Net service revenue	$	48.5		$	47.8		1.5 %
Cost of services		24.1			21.5		12.1 %
Gross margin		50.3 %			55.0 %
General & administrative expenses	$	16.1		$	15.5		3.9 %
Equity earnings / noncontrolling interest	$	—		$	0.1
Adjusted EBITDA	$	8.3		$	10.7		(22.4) %
% Adj. EBITDA margin		17.1 %			22.4 %
Operational metrics (Actual Amounts)
Total admissions		2,837			2,835		0.1 %
Same-store total admissions growth							(4.1) %
Patient days		311,465			313,718		(0.7) %
Discharged average length of stay		108			109		(0.9) %
Average daily census		3,423			3,447		(0.7) %
Revenue per day	$	156		$	152		2.6 %
Cost per day	$	77		$	69		11.6 %

Net service revenue increased year over year primarily due to increased Medicare reimbursement rates.

Adjusted EBITDA decreased year over year primarily due to higher cost of services resulting from increased labor costs. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses.

TAX MATTERS AGREEMENT

Enhabit also announced today that it is undertaking steps to attempt to satisfy the conditions in its Tax Matters Agreement (“TMA”), dated June 30, 2022, with Encompass Health Corporation relating to certain transactions involving the Company. The conditions in the TMA include securing a tax opinion of legal counsel, satisfactory to Encompass Health in its sole and absolute discretion, that the actions taken by Enhabit would not jeopardize the tax-free treatment of the spin-off of Enhabit.

Upon satisfaction of these conditions, the Enhabit board, with the assistance of independent advisors, intends to launch a strategic alternatives process. As part of any such process, the board expects it would consider a wide range of options for the company including, among other things, a potential sale, merger or other strategic transaction. There can be no assurance that the conditions in the TMA will be satisfied, that Enhabit will initiate such a process, or if launched, that a process would result in Enhabit pursuing a particular transaction or other strategic outcome.

GUIDANCE

The Company revised its full-year 2023 guidance as follows:

($ in millions, except per share data)
Full-Year 2023	2023 Original Guidance	2023 Revised Guidance
Net Service Revenue	$1,110 to $1,140	$1,057 to $1,065
Adjusted EBITDA	$125 to $140	$100 to $107
Adjusted EPS	$0.50 to $0.89	$0.28 to $0.46

For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 AM Eastern Time on August 10, 2023 to discuss its results for the second quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/923162031. Following the call, a replay will be available at Enhabit’s investor website.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 108 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation of non-GAAP financial measures

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, leverage ratios, adjusted EPS, and adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP.

The Company is unable to reconcile the guidance for Adjusted EBITDA and adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding reconciliations of non-GAAP financial measures

This press release contains the reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited)
	Three Months Ended June 30,							Six Months Ended June 30,
		2023				2022			2023				2022
	($ in millions, except per share data)
Net service revenue	$	262.3			$	268.0		$	527.4			$	542.3
Cost of service, excluding depreciation and amortization		135.5				130.3			268.1				260.0
General and administrative expenses		107.8				102.2			218.3				202.9
Depreciation and amortization		7.7				8.2			15.5				16.7
Impairment of goodwill		85.8				—			85.8				—
Operating income		(74.5	)			27.3			(60.3	)			62.7
Interest expense and amortization of debt discounts and fees		10.3				0.1			19.8				0.1
Other income		(0.1	)			—			(0.1	)			—
(Loss) income before income taxes and noncontrolling interests		(84.7	)			27.2			(80.0	)			62.6
Income tax (benefit) expense		(10.6	)			6.4			(9.1	)			15.1
Net (loss) income		(74.1	)			20.8			(70.9	)			47.5
Less: Net income attributable to noncontrolling interests		0.3				0.7			0.8				1.3
Net (loss) income attributable to Enhabit, Inc.	$	(74.4	)		$	20.1		$	(71.7	)		$	46.2
Weighted average common shares outstanding:
Basic		49.8				49.6			49.8				49.6
Diluted		49.8				49.6			49.8				49.6
(Loss) earnings per common share:
Basic (loss) earnings per share attributable to Enhabit, Inc. common stockholders	$	(1.49	)		$	0.41		$	(1.44	)		$	0.93
Diluted (loss) earnings per share attributable to Enhabit, Inc. common stockholders	$	(1.49	)		$	0.41		$	(1.44	)		$	0.93

Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited)
	June 30, 2023			December 31, 2022
	($ in millions)
Assets
Current assets:
Cash and cash equivalents	$	34.4		$	22.9
Restricted cash		2.1			4.3
Accounts receivable		147.6			149.6
Income tax receivable		3.9			11.4
Prepaid expenses and other current assets		11.6			23.6
Total current assets		199.6			211.8
Property and equipment, net		18.5			20.4
Operating lease right-of-use assets		49.3			42.0
Goodwill		1,061.7			1,144.8
Intangible assets, net		91.2			102.6
Other long-term assets		5.9			5.2
Total assets	$	1,426.2		$	1,526.8
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	$	22.5		$	23.1
Current operating lease liabilities		11.7			14.0
Accounts payable		5.4			3.8
Accrued payroll		32.8			35.5
Refunds due patients and other third-party payors		7.1			8.3
Accrued medical insurance		8.2			7.5
Other current liabilities		35.8			40.7
Total current liabilities		123.5			132.9
Long-term debt, net of current portion		539.3			560.0
Long-term operating lease liabilities		37.5			28.1
Deferred income tax liabilities		18.1			28.6
Other long-term liabilities		0.6			1.9
		719.0			751.5
Commitments and contingencies
Redeemable noncontrolling interests		5.1			5.2
Stockholders’ equity:
Enhabit, Inc. stockholders’ equity:		675.2			741.7
Noncontrolling interests		26.9			28.4
Total stockholders’ equity		702.1			770.1
Total liabilities and stockholders’ equity	$	1,426.2		$	1,526.8

Enhabit, Inc. and Subsidiaries Condensed Consolidated Cash Flows (Unaudited)
	Six Months Ended June 30,
		2023				2022
	($ in millions)
Cash flows from operating activities:
Net (loss) income	$	(70.9	)		$	47.5
Adjustments to reconcile net (loss) income to net cash provided by operating activities—
Depreciation and amortization		15.5				16.7
Amortization of debt related costs		0.5				—
Impairment of goodwill		85.8				—
Stock-based compensation		4.1				2.5
Deferred tax benefit		(11.0	)			(1.4	)
Other, net		0.9				(0.6	)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable		1.9				13.4
Prepaid expenses and other assets		19.2				(2.7	)
Accounts payable		1.5				(0.8	)
Accrued payroll		(2.6	)			6.2
Other liabilities		(5.7	)			(5.8	)
Net cash provided by operating activities		39.2				75.0
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired		(2.8	)			—
Purchases of property and equipment		(1.7	)			(4.5	)
Other, net		0.5				1.0
Net cash used in investing activities		(4.0	)			(3.5	)
Cash flows from financing activities:
Principal borrowings on term loan		—				400.0
Principal payments on term loan		(10.0	)			—
Principal payments on debt		—				(0.4	)
Borrowings on revolving credit facility		—				170.0
Payments on revolving credit facility		(10.0	)			—
Principal payments under finance lease obligations		(1.8	)			(2.6	)
Debt issuance costs		(1.1	)			(4.4	)
Distributions paid to noncontrolling interests of consolidated affiliates		(2.5	)			(0.7	)
Contributions from Encompass		—				59.8
Distributions to Encompass		—				(654.9	)
Contributions from noncontrolling interests of consolidated affiliates		—				7.4
Other		(0.5	)			—
Net cash used in financing activities		(25.9	)			(25.8	)
Increase in cash, cash equivalents, and restricted cash		9.3				45.7
Cash, cash equivalents, and restricted cash at beginning of year		27.2				8.0
Cash, cash equivalents, and restricted cash at end of period	$	36.5			$	53.7

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share
	Three Months Ended June 30,							Six Months Ended June 30,
		2023				2022			2023				2022
Earnings per share, as reported	$	(1.49	)		$	0.41		$	(1.44	)		$	0.93
Adjustments, net of tax:
Impairment of goodwill		1.50				—			1.50				—
Unusual or nonrecurring items that are not typical of ongoing operations(1)		0.03				0.06			0.07				0.09
Income tax adjustments(2)		—				—			0.01				—
Adjusted earnings per share(3)	$	0.04			$	0.47		$	0.14			$	1.02

(1)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.
(2)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(3)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share
	Q2 QTD
	2023
				Adjustments
	As Reported				Impairment of Goodwill				Unusual or nonrecurring items that are not typical of ongoing operations				Income Tax Adjustments(3)			As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	23.9			$	—			$	—			$	—		$	23.9
Impairment of goodwill		(85.8	)			85.8				—				—			—
Interest expense and amortization of debt discounts and fees		(10.3	)							—				—			(10.3	)
Depreciation and amortization		(7.7	)			—				—				—			(7.7	)
Unusual or nonrecurring items that are not typical of ongoing operations(2)		(2.6	)			—				2.6				—			—
Stock-based compensation		(2.6	)			—				—				—			(2.6	)
Gain on disposal or impairment of assets		0.1				—				—				—			0.1
Net loss before income tax expense, including noncontrolling interests		(85.0	)			85.8				2.6				—			3.4
Income tax benefit (expense)		10.6				(11.1	)			(1.0	)			0.1			(1.4	)
Net (loss) income attributable to Enhabit	$	(74.4	)		$	74.7			$	1.6			$	0.1		$	2.0
Diluted earnings per share(4)	$	(1.49	)		$	1.50			$	0.03			$	—		$	0.04
Diluted shares		49.8															49.8

(1)	See reconciliation of net income to Adjusted EBITDA below.
(2)	Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense.
(3)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share
	Q2 QTD
	2022
					Adjustments
	As Reported				Unusual or nonrecurring items that are not typical of ongoing operations				As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	40.3			$	—			$	40.3
Depreciation and amortization		(8.2	)			—				(8.2	)
Unusual or nonrecurring items that are not typical of ongoing operations(2)		(4.1	)			4.1				—
Stock-based compensation		(1.2	)			—				(1.2	)
Stock-based compensation included in overhead allocation		(0.6	)			—				(0.6	)
Gain on disposal or impairment of assets		0.4				—				0.4
Interest expense and amortization of debt discounts and fees		(0.1	)			—				(0.1	)
Income before income tax expense		26.5				4.1				30.6
Provision for income tax expense		(6.4	)			(1.0	)			(7.4	)
Net income attributable to Enhabit	$	20.1			$	3.1			$	23.2
Diluted earnings per share(3)	$	0.41			$	0.06			$	0.47
Diluted shares used in calculation		49.6								49.6

(1)	See reconciliation of net income to Adjusted EBITDA below.
(2)	Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review.
(3)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share
	YTD
	2023
					Adjustments
	As Reported				Impairment of Goodwill				Unusual or nonrecurring items that are not typical of ongoing operations				Income Tax Adjustments(3)			As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	49.2			$	—			$	—			$	—		$	49.2
Impairment of goodwill		(85.8	)			85.8				—				—			—
Interest expense and amortization of debt discounts and fees		(19.8	)			—				—				—			(19.8	)
Depreciation and amortization		(15.5	)			—				—				—			(15.5	)
Unusual or nonrecurring items that are not typical of ongoing operations(2)		(4.9	)			—				4.9				—			—
Stock-based compensation		(4.1	)			—				—				—			(4.1	)
Gain on disposal or impairment of assets		0.1				—				—				—			0.1
Net loss before income taxes, including noncontrolling interests		(80.8	)			85.8				4.9				—			9.9
Income tax benefit (expense)		9.1				(11.1	)			(1.6	)			0.5			(3.1	)
Net (loss) income attributable to Enhabit	$	(71.7	)		$	74.7			$	3.3			$	0.5		$	6.8
Diluted earnings per share(4)	$	(1.44	)		$	1.50			$	0.07			$	0.01		$	0.14
Diluted shares		49.8															49.8

(1)	See reconciliation of net income to Adjusted EBITDA below.
(2)	Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense.
(3)	Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(4)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share
	YTD
	2022
					Adjustments
	As Reported				Unusual or nonrecurring items that are not typical of ongoing operations				As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	87.3			$	—			$	87.3
Depreciation and amortization		(16.7	)			—				(16.7	)
Unusual or nonrecurring items that are not typical of ongoing operations(2)		(6.1	)			6.1				—
Stock-based compensation		(2.5	)			—				(2.5	)
Stock-based compensation included in overhead allocation		(1.1	)			—				(1.1	)
Gain on disposal or impairment of assets		0.5				—				0.5
Interest expense and amortization of debt discounts and fees		(0.1	)			—				(0.1	)
Income before income tax expense		61.3				6.1				67.4
Provision for income tax expense		(15.1	)			(1.5	)			(16.6	)
Net income attributable to Enhabit	$	46.2			$	4.6			$	50.8
Diluted earnings per share(3)	$	0.93			$	0.09			$	1.02
Diluted shares used in calculation		49.6								49.6

(1)	See reconciliation of net income to Adjusted EBITDA below.
(2)	Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review.
(3)	Adjusted EPS may not sum due to rounding.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Income to Adjusted EBITDA
	Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
	($ in millions)
Net (loss) income	$	(74.1	)		$	20.8			$	(70.9	)		$	47.5
Impairment of goodwill		85.8				—				85.8				—
Income tax (benefit) expense		(10.6	)			6.4				(9.1	)			15.1
Interest expense and amortization of debt discounts and fees		10.3				0.1				19.8				0.1
Depreciation and amortization		7.7				8.2				15.5				16.7
Unusual or nonrecurring items that are not typical of ongoing operations(1)		2.6				4.1				4.9				6.1
Stock-based compensation		2.6				1.2				4.1				2.5
Net income attributable to noncontrolling interests		(0.3	)			(0.7	)			(0.8	)			(1.3	)
Gain on disposal or impairment of assets		(0.1	)			(0.4	)			(0.1	)			(0.5	)
Stock-based compensation included in overhead allocation		—				0.6				—				1.1
Adjusted EBITDA	$	23.9			$	40.3			$	49.2			$	87.3

(1)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA
	Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
	($ in millions)
Net cash provided by operating activities	$	9.6			$	33.6			$	39.2			$	75.0
Interest expense, excluding amortization of debt discounts and fees		10.1				0.1				19.3				0.1
Unusual or nonrecurring items that are not typical of ongoing operations(1)		2.6				4.1				4.9				6.1
Change in assets and liabilities, excluding derivative instruments		1.2				(5.0	)			(15.0	)			(10.3	)
Current portion of income tax expense		0.7				7.6				1.9				16.5
Net income attributable to noncontrolling interests in continuing operations		(0.3	)			(0.7	)			(0.8	)			(1.3	)
Stock-based compensation included in overhead allocation		—				0.6				—				1.1
Other		—				—				(0.3	)			0.1
Adjusted EBITDA	$	23.9			$	40.3			$	49.2			$	87.3

(1)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.

Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
	Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
	($ in millions)
Net cash provided by operating activities	$	9.6			$	33.6			$	39.2			$	75.0
Capital expenditures for maintenance		(1.1	)			(0.3	)			(1.7	)			(2.6	)
Other working capital adjustments		(0.5	)			(0.4	)			(1.0	)			(0.9	)
Distributions paid to noncontrolling interests of consolidated affiliates		—				(0.2	)			(2.5	)			(0.7	)
Items non-indicative of ongoing operating performance:
Unusual or nonrecurring items that are not typical of ongoing operations(1)		2.6				4.1				4.9				6.1
Stock-based compensation included in overhead allocation		—				0.6				—				1.1
Adjusted free cash flow	$	10.6			$	37.4			$	38.9			$	78.0

(1)	Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. In addition, with respect to the Tax Matters Agreement (TMA) and the potential launch of a strategic alternative process, these factors include, our ability to receive Encompass Health Corporation’s approval to pursue a strategic transaction as required under the TMA and our ability to successfully pursue and complete a strategic transaction, as discussed above. Our Form 10-K and subsequent quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230809036551/en/

Investor Relations Contact

Jordan Loyd

InvestorRelations@ehab.com

469-860-6061

Media Contact

Erin Volbeda

Media@ehab.com

972-338-5141

Source: Enhabit, Inc.

FAQ

What were Enhabit's Q2 2023 net service revenue and net loss?

Enhabit reported net service revenue of $262.3 million and a net loss of $74.1 million for Q2 2023.

How many new contracts did Enhabit negotiate with Medicare Advantage payors?

Enhabit negotiated ten new contracts with Medicare Advantage payors.

How many new full-time nursing hires did Enhabit make in Q2 2023?

Enhabit made 203 net new full-time nursing hires in Q2 2023.

How does Enhabit's 30-day hospital readmission rate compare to the national average?

Enhabit's 30-day hospital readmission rate is 370 basis points better than the national average.

What is Enhabit's intent regarding a strategic alternatives process?

Enhabit intends to launch a strategic alternatives process, subject to conditions in the Tax Matters Agreement.

What were Enhabit's revised full-year 2023 guidance ranges?

Enhabit revised its full-year 2023 guidance, with net service revenue ranging from $1,057 to $1,065 million, adjusted EBITDA ranging from $100 to $107 million, and adjusted EPS ranging from $0.28 to $0.46.